704 related articles for article (PubMed ID: 19746571)
21. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Ridker PM;
Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
[No Abstract] [Full Text] [Related]
22. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
Duvernoy CS; Blumenthal R
Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
[No Abstract] [Full Text] [Related]
23. [The JUPITER study: critical review of final results].
Urbinati S; Romanazzi S; Gambetti S
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
[TBL] [Abstract][Full Text] [Related]
24. [Cardiology 2008].
Hoppe UC; Erdmann E
Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1341-3. PubMed ID: 18553258
[No Abstract] [Full Text] [Related]
25. The JUPITER trial: results, controversies, and implications for prevention.
Ridker PM
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):279-85. PubMed ID: 20031849
[No Abstract] [Full Text] [Related]
26. [Comment from the lipidologic viewpoint].
Riesen WF
Praxis (Bern 1994); 2009 Feb; 98(3):125-7. PubMed ID: 19180437
[No Abstract] [Full Text] [Related]
27. Public health. U.S. panel favors wider use of preventive drug treatment.
Couzin-Frankel J
Science; 2010 Jan; 327(5962):130-1. PubMed ID: 20056859
[No Abstract] [Full Text] [Related]
28. Rosuvastatin in patients with elevated C-reactive protein.
Pierard LA
N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277
[No Abstract] [Full Text] [Related]
29. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
30. Is Jupiter also a god of primary prevention?
Accad M; Fred HL
Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621
[No Abstract] [Full Text] [Related]
31. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
[No Abstract] [Full Text] [Related]
32. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.
Underhill HR; Yuan C; Zhao XQ; Kraiss LW; Parker DL; Saam T; Chu B; Takaya N; Liu F; Polissar NL; Neradilek B; Raichlen JS; Cain VA; Waterton JC; Hamar W; Hatsukami TS
Am Heart J; 2008 Mar; 155(3):584.e1-8. PubMed ID: 18294500
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
Willich SN; Müller-Nordhorn J; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H
Am Heart J; 2004 Dec; 148(6):1060-7. PubMed ID: 15632894
[TBL] [Abstract][Full Text] [Related]
34. [No reason to start treatment with statins in patients with moderate to severe heart failure].
Stalenhoef AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular risk in uremic patients: darkness after AURORA.
Robles NR; Macias JF
Ren Fail; 2010 Jan; 32(2):269-72. PubMed ID: 20199190
[No Abstract] [Full Text] [Related]
36. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit.
Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361
[No Abstract] [Full Text] [Related]
37. [Ongoing trials and future prospects].
Baldasseroni S; Fabbri G; Maggioni AP
Ital Heart J; 2003 Dec; 4 Suppl 7():58S-64S. PubMed ID: 14983747
[TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; MacFadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
N Engl J Med; 2008 Nov; 359(21):2195-207. PubMed ID: 18997196
[TBL] [Abstract][Full Text] [Related]
39. [Statins in primary prophylaxis of cardiovascular diseases].
Kobalava ZhD; Villeval'de SV
Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392
[TBL] [Abstract][Full Text] [Related]
40. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study.
Laks T; Keba E; Leiner M; Merilind E; Petersen M; Reinmets S; Väli S; Sööt T; Otter K
Vasc Health Risk Manag; 2008; 4(6):1407-16. PubMed ID: 19337553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
